


## NVP-BSK805

<b>Cat. No.:</b>	HY-14722												
<b>CAS No.:</b>	1092499-93-8												
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>28</sub> F <sub>2</sub> N <sub>6</sub> O												
<b>Molecular Weight:</b>	490.55												
<b>Target:</b>	JAK												
<b>Pathway:</b>	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt												
<b>Storage:</b>	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (203.85 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.0385 mL	10.1926 mL	20.3853 mL
	5 mM	0.4077 mL	2.0385 mL	4.0771 mL
	10 mM	0.2039 mL	1.0193 mL	2.0385 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

NVP-BSK805 is an ATP-competitive JAK2 inhibitor, with IC<sub>50</sub>s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

JAK2 JH1 0.48 nM (IC <sub>50</sub> )	FL JAK2 V617F 0.56 nM (IC <sub>50</sub> )	FL JAK2 wt 0.58 nM (IC <sub>50</sub> )	TYK2 JH1 10.76 nM (IC <sub>50</sub> )
JAK3 JH1 18.68 nM (IC <sub>50</sub> )	JAK1 JH1 31.63 nM (IC <sub>50</sub> )		

#### In Vitro

NVP-BSK805 (BSK 805) is a JAK2 inhibitor, with IC<sub>50</sub>s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively. NVP-BSK805 inhibits the full-length wild-type JAK2 (FL JAK2 wt) and FL JAK2 V617F activity, with IC<sub>50</sub>s of 0.58 ± 0.03 and 0.56 ± 0.04 nM. NVP-BSK805 is ATP-competitive, with acclulated K<sub>i</sub> of 0.43 ± 0.02 nM. NVP-BSK805 suppresses the growth of JAK2<sup>V617F</sup>-bearing acute myeloid leukemia cell lines with GI<sub>50</sub> of <100 nM. NVP-BSK805 blocks the STAT5 phosphorylation at ≥100 nM concentrations, and shows a bias for JAK2 over JAK1 and JAK3 inhibition in the JAK2<sup>V617F</sup>-mutant cell lines<sup>[1]</sup>.

NVP-BSK805 (5  $\mu$ M) improves P-gp inhibitory activity. NVP-BSK805 increases sensitization of drug-resistant KBV20C cancer cells to VIC treatment at 10  $\mu$ M, and such an effect is more effective than a 5  $\mu$ M dose<sup>[2]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

NVP-BSK805 (BSK 805; 150 mg/kg, p.o.) blocks STAT5 phosphorylation, splenomegaly, and leukemic cell spreading in a Ba/F3 JAK2<sup>V617F</sup> cell-driven mouse model<sup>[1]</sup>.  
NVP-BSK805 (50, 75, and 100 mg/kg, p.o.) also suppresses rhEpo-mediated polycythemia and splenomegaly in BALB/c mice<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Cell Assay<sup>[1]</sup>

The antiproliferative activity of JAK2 inhibitors is determined by incubating cells for 72 hours (96 hours for MB-02 and MUTZ-8 cells) with an 8-point concentration range of NVP-BSK805 and cell proliferation relative to NVP-BSK805 is measured using the colorimetric WST-1 cell viability readout. Of each triplicate treatment, the mean is calculated and these data are plotted in XLfit 4 to determine the half-maximal growth inhibition (GI<sub>50</sub>) values<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Animal Administration<sup>[1]</sup>

Mice<sup>[1]</sup>  
Concomitantly with NVP-BSK805 treatment, female BALB/c mice receive daily s.c. injections (in 100  $\mu$ L saline buffer) of 10 units of rhEpo for 4 consecutive days. Controls are injected corresponding volumes of saline buffer. Mice are sacrificed 24 hours after the final dose and total blood, spleen, and bone marrow are taken for further analysis. Animals are 8 to 10 weeks of age at treatment start (20-25 g body weight) and are kept under optimal hygienic conditions with free access to food and water<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Patent. US20180263995A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Baffert F, et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. *Mol Cancer Ther.* 2010 Jul;9(7):1945-55.

[2]. Cheon JH, et al. The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine. *Biochem Biophys Res Commun.* 2017 Sep 2;490(4):1176-1182.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA